Hillstar Bio
PrivateLast Round
Series A
Mar 25, 2025
Total Funding Raised
$67M
Company Overview
Hillstar Bio is a biotechnology company that develops next-generation precision immunology therapies for autoimmune diseases by selectively targeting and depleting pathogenic immune cells.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hillstar Bio Comps
Public and private peers based on sector, stage, and business model.
Hillstar Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 25, 2025 |
Hillstar Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Droia Ventures | Series A |
| Frazier Life Sciences | Series A |
| Novo Holdings | Series A |
| LifeArc Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 28, 2025
Maude Tessier appointed as new Chief Operating Officer.
- Mar 25, 2025
$67M round completed.
Hillstar Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Hillstar Bio's valuation, stock price, and market status.
